Physician profile
Christopher Chong
NPI 1831329978
$11,028.26
in general payments reported to CMS, 2019-2025
36 companies · $3,276 in 2025
The $3,276 reported for 2025 was more than what 79% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,809 · 2020: $546 · 2021: $151 · 2022: $1,832 · 2023: $1,642 · 2024: $1,773 · 2025: $3,276.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,675 · Education: $16.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,674.55 |
| Education | $16.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,523.49 | 2019-2025 | Rinvoq, Humira, Skyrizi |
| Amgen INC. | $1,494.81 | 2020-2025 | Krystexxa, Tavneos, Evenity |
| Pfizer INC. | $977.20 | 2019-2025 | |
| Ucb, INC. | $871.46 | 2019-2025 | Bimzelx, Cimzia |
| Horizon Therapeutics Plc | $788.44 | 2019-2023 | Krystexxa |
| Astrazeneca Pharmaceuticals Lp | $583.80 | 2022-2025 | Saphnelo |
| Glaxosmithkline, LLC. | $567.40 | 2019-2025 | Benlysta |
| Novartis Pharmaceuticals Corporation | $523.52 | 2019-2025 | |
| Genentech USA, INC. | $229.92 | 2019-2023 | Actemra |
| Sobi, INC | $168.04 | 2022-2025 | |
| Lilly USA, LLC | $162.05 | 2019-2024 | Taltz |
| Celgene Corporation | $146.10 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $123.05 | 2019-2025 | Orencia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $111.92 | 2020-2024 | Cyltezo, Ofev |
| Ani Pharmaceuticals, INC. | $100.16 | 2022-2025 | Purified Cortrophin Gel |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $96.25 | 2020-2025 | Acthar |
| Organon LLC | $81.04 | 2023-2025 | Hadlima, Renflexis |
| Octapharma USA, INC. | $59.40 | 2022 | |
| Aurinia Pharma U.S., INC. | $46.60 | 2022-2024 | Lupkynis |
| Fresenius Kabi USA, LLC | $42.74 | 2023-2025 | Idacio |
| Celltrion USA INC. | $36.44 | 2023-2024 | Vegzelma, Yuflyma |
| Mallinckrodt Enterprises LLC | $34.70 | 2019 | |
| Grifols USA, LLC | $28.88 | 2022 | |
| Genzyme Corporation | $25.37 | 2023 | |
| Janssen Biotech, INC. | $21.86 | 2025 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $21.30 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $20.51 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $18.25 | 2025 | Opsumit, Uptravi |
| Kiniksa Pharmaceuticals, Ltd. | $17.79 | 2023 | Arcalyst |
| Gilead Sciences, INC. | $17.15 | 2019 | |
| Oxford Immunotec USA INC | $16.38 | 2019 | |
| Merck Sharp & Dohme LLC | $16.08 | 2019 | |
| Avion Pharmaceuticals | $15.27 | 2020 | |
| Scilex Pharmaceuticals INC. | $14.38 | 2025 | |
| Hikma Pharmaceuticals USA | $14.34 | 2019 | |
| Ferring Pharmaceuticals INC. | $12.17 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Chong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.